Acrux Limited (ACR.AX)
AUD 0.02
(-8.33%)
AUD 0.02
(-8.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.68 Million AUD | 1.5% |
| 2023 | 5.6 Million AUD | -9.38% |
| 2022 | 6.18 Million AUD | 7.89% |
| 2021 | 5.73 Million AUD | 1.04% |
| 2020 | 5.67 Million AUD | 127.15% |
| 2019 | 2.49 Million AUD | -0.87% |
| 2018 | 2.51 Million AUD | -25.5% |
| 2017 | 3.38 Million AUD | -64.34% |
| 2016 | 9.48 Million AUD | 20.48% |
| 2015 | 7.87 Million AUD | -29.51% |
| 2014 | 11.16 Million AUD | 81.76% |
| 2013 | 6.14 Million AUD | 13.83% |
| 2012 | 5.39 Million AUD | -59.38% |
| 2011 | 13.28 Million AUD | 323.57% |
| 2010 | 3.13 Million AUD | -15.86% |
| 2009 | 3.72 Million AUD | 18.02% |
| 2008 | 3.15 Million AUD | 48.75% |
| 2007 | 2.12 Million AUD | -19.92% |
| 2006 | 2.65 Million AUD | 64.47% |
| 2005 | 1.61 Million AUD | 19.52% |
| 2004 | 1.34 Million AUD | 14.18% |
| 2003 | 1.18 Million AUD | 35.69% |
| 2002 | 870.46 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 6.67 Million AUD | 19.19% |
| 2024 Q4 | 5.68 Million AUD | 0.0% |
| 2024 Q2 | 6.37 Million AUD | 0.0% |
| 2023 FY | 5.6 Million AUD | -9.38% |
| 2023 Q4 | 5.6 Million AUD | 0.0% |
| 2023 Q2 | 4.38 Million AUD | 0.0% |
| 2022 Q4 | 6.18 Million AUD | 0.0% |
| 2022 FY | 6.18 Million AUD | 7.89% |
| 2022 Q2 | 4.01 Million AUD | 0.0% |
| 2021 Q4 | 5.73 Million AUD | 0.0% |
| 2021 FY | 5.73 Million AUD | 1.04% |
| 2021 Q2 | 5.63 Million AUD | 0.0% |
| 2020 FY | 5.67 Million AUD | 127.15% |
| 2020 Q2 | 4.44 Million AUD | 0.0% |
| 2020 Q4 | 5.67 Million AUD | 0.0% |
| 2019 Q2 | 1.82 Million AUD | 0.0% |
| 2019 Q4 | 2.49 Million AUD | 0.0% |
| 2019 FY | 2.49 Million AUD | -0.87% |
| 2018 FY | 2.51 Million AUD | -25.5% |
| 2018 Q4 | 2.51 Million AUD | 0.0% |
| 2018 Q2 | 1.82 Million AUD | 0.0% |
| 2017 Q2 | 4.83 Million AUD | 0.0% |
| 2017 FY | 3.38 Million AUD | -64.34% |
| 2017 Q4 | 3.38 Million AUD | 0.0% |
| 2016 Q4 | 9.48 Million AUD | 0.0% |
| 2016 FY | 9.48 Million AUD | 20.48% |
| 2016 Q2 | 5.06 Million AUD | 0.0% |
| 2015 FY | 7.87 Million AUD | -29.51% |
| 2015 Q4 | 7.87 Million AUD | 0.0% |
| 2015 Q2 | 4.34 Million AUD | 0.0% |
| 2014 FY | 11.16 Million AUD | 81.76% |
| 2014 Q4 | 11.16 Million AUD | 0.0% |
| 2014 Q2 | 13.16 Million AUD | 0.0% |
| 2013 Q4 | 6.14 Million AUD | 0.0% |
| 2013 FY | 6.14 Million AUD | 13.83% |
| 2013 Q2 | 1.24 Million AUD | 0.0% |
| 2012 FY | 5.39 Million AUD | -59.38% |
| 2012 Q4 | 5.39 Million AUD | 0.0% |
| 2011 Q4 | 13.28 Million AUD | 0.0% |
| 2011 FY | 13.28 Million AUD | 323.57% |
| 2010 Q4 | 3.13 Million AUD | 0.0% |
| 2010 FY | 3.13 Million AUD | -15.86% |
| 2009 Q4 | 3.72 Million AUD | 0.0% |
| 2009 FY | 3.72 Million AUD | 18.02% |
| 2008 FY | 3.15 Million AUD | 48.75% |
| 2008 Q4 | 3.15 Million AUD | 0.0% |
| 2007 FY | 2.12 Million AUD | -19.92% |
| 2007 Q4 | 2.12 Million AUD | 0.0% |
| 2006 Q4 | 2.65 Million AUD | 0.0% |
| 2006 FY | 2.65 Million AUD | 64.47% |
| 2005 FY | 1.61 Million AUD | 19.52% |
| 2005 Q4 | 1.61 Million AUD | 0.0% |
| 2004 FY | 1.34 Million AUD | 14.18% |
| 2004 Q4 | 1.34 Million AUD | 0.0% |
| 2003 FY | 1.18 Million AUD | 35.69% |
| 2002 FY | 870.46 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -60.534% |
| Actinogen Medical Limited | 1.61 Million AUD | -252.056% |
| AnteoTech Limited | 4.07 Million AUD | -39.549% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -134.349% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -176.52% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -1753.355% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -4.816% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -65.957% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -504.01% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -1443.51% |
| Biome Australia Limited | 5.37 Million AUD | -5.839% |
| Biotron Limited | 737.5 Thousand AUD | -671.11% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -52.382% |
| BTC Health Limited | 203.94 Thousand AUD | -2688.456% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 55.581% |
| CSL Limited | 27.88 Billion AUD | 99.98% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 31.743% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 79.77% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -385.63% |
| Dimerix Limited | 13.89 Million AUD | 59.066% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -34.472% |
| Hexima Limited | 248.67 Thousand AUD | -2186.967% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -443.886% |
| Immuron Limited | 2.84 Million AUD | -100.209% |
| Immutep Limited | 10.97 Million AUD | 48.204% |
| Imugene Limited | 33.14 Million AUD | 82.841% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -1217.564% |
| Memphasys Limited | 5.59 Million AUD | -1.692% |
| Nanollose Limited | 465.64 Thousand AUD | -1121.322% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 86.701% |
| Noxopharm Limited | 1.28 Million AUD | -341.327% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -6537.256% |
| Nyrada Inc. | 855.63 Thousand AUD | -564.654% |
| Orthocell Limited | 22.08 Million AUD | 74.247% |
| PharmAust Limited | 896.6 Thousand AUD | -534.28% |
| Patrys Limited | 691.36 Thousand AUD | -722.576% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -58.662% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -249.77% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -144.543% |
| PYC Therapeutics Limited | 10.18 Million AUD | 44.158% |
| Race Oncology Limited | 1.91 Million AUD | -196.75% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 87.273% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 64.218% |
| Starpharma Holdings Limited | 8.69 Million AUD | 34.617% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 97.72% |
| Tissue Repair Ltd | 1.35 Million AUD | -320.977% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 39.219% |